Created by Cura, the Renata Thormann Procianoy award aims to create a culture of philanthropy, raise resources for scientific research, and encourage oncologists to develop research that helps in the search for a cure for cancer. The award was launched at the Best of ASCO conference, which took place from June 14-15, 2019. In its first edition, Brazilian papers submitted to the Annual Meeting of the American Society of Clinical Oncology (ASCO) were considered. A technical committee made up of research doctors associated with LACOG chose Dr. Thiago Bueno's work as the winner.
The award was inspired by the story Nora Thormann Porcianoy, who had the help of her daughter Renata Thormann Procianoy in the search for research that would help diagnose what was wrong with her breast implants. The daughter gave up everything to commit herself to this mission, which, after two years, resulted in the inclusion of Nora's case in a study coordinated by doctor Dr. Roberto Miranda at the MD Anderson Hospital, University of Texas — USA. Research identified and treated Nora. Some years later, with Nora having recovered from cancer, her daughter Renata died in a car accident in 2013. The family transformed pain into love with the decision to contribute to work involving research to cure cancer. Then, through the Cura Project, they made a donation to LACOG, an institution that develops and coordinates multicentric oncology research in Latin America, with headquarters in Brazil. Learn more about this story in the video below:
The prize trophy was created and donated by the artist Fernanda Frangetto
Fernanda Frangetto Maksoud, visual artist, works in different media: sculpture, installation, painting and drawing. He studied at the Centro Universitário de Belas Artes and specialized in sculpture at the Brazilian Museum of Sculpture, both in São Paulo. His works have been presented at art institutions in the USA and Brazil, such as the NARS Foundation (New York); DORCAM Doral Contemporary Art Museum, Marco Island Center for the Arts, Magnetic Pompano (Florida); Casa das Nações Unidas (Brasília); Marcos Amaro Foundation, Central Bank of Brazil and Brazilian Society of Japanese Culture (São Paulo). He created sculptures and trophies for the “São Paulo Association of Art Critics” (Prize APCA), or Fashion Brazil Miami. The City of Doral - Government Center, in Florida, invited her to create sculptures in honor of the national fight against cancer. These sculptures were donated to Doral City Hall,” Commissioners Office of Miami-Dade” and the “American Cancer Society”. At the special invitation of the “Cura Project Institute Association”, the “Renata Thormann Procianoy Award 2019” was designed. Fernanda Frangetto received the Grand Gold Award at the Bunkyo Hall and was one of the consecutive winners of the Focus Brazil Visual Arts Award. Fernanda Frangetto has lectured at numerous art events and her works are included in collections such as the Consulate General of Brazil in Miami, the Marcos Amaro Foundation and the Brazilian Society for Japanese Culture. Fernanda Frangetto is represented by the Duo Art Gallery in Miami.
The evening of Friday, June 14, 2019 was filled with good music and solidarity. Participants at the Best Of ASCO Congress and society in general participated in the show “Jazz for Oncological Research” with conductor Osmar Barutti and singer Alba Santos.
At the time there was also a presentation from the winner of the first Renata Thormann Procianoy scientific research prize to Dr. Thiago Bueno. Creating a culture of philanthropy, raising resources for scientific research, and encouraging young oncologists to develop research that helps in the search for a cure for cancer are among the Objectives of the award created by the Cura Project.The show took place at Blue Note in the city of São Paulo-SP and was supported by Armazem Entertainment.
Dr. Thiago Bueno was announced the winner during the Best of ASCO® Annual Meeting, organized by LACOG on June 14-15, 2019 at the Hotel Transamérica in São Paulo/SP. Thiago Bueno de Oliveira has a PhD in Oncology from the Antônio Prudente Foundation; Senior Physician in the Department of Clinical Oncology; Leader of Clinical Oncology at the Head and Neck Reference Center of the AC Camargo Cancer Center; and Member of the Brazilian Head and Neck Cancer Group.
Check out Dr. Thiago's report about his research:My work, which has already been completed and was my doctoral thesis, involves the evaluation of circulating tumor cells (CTCs) analyzed in blood samples, before and after treatment in patients with locally advanced head and neck cancer. 83 patients with epidermoid carcinoma of the oral cavity, oropharynx, larynx and hypopharynx, with locally advanced disease and candidates for treatment with curative intent were included prospectively. CTCs were detected in 94 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} of the patients, and the number of CTCs was significantly correlated with survival and response to treatment. For each increase of 1 CTC/ml before treatment, there was a significant increase of 18 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}, 16 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} in the risk of disease recurrence or progression, and a reduction of 26 {46cf1cf1 a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} in the chance of a complete response to treatment. In addition, the expression of biomarkers in CTCs, some of them with prognostic and predictive potential, was studied. Counting CTCs before treatment was also shown to be a potential predictor of benefit from the use of chemotherapy before (induction) radiation therapy. High CTC counts after treatment and unfavorable kinetics (significant increases in CTCs considering the values before and after treatment) were also correlated with worse survival. The relevance of the results lies in the possibility of identifying patients with a higher risk of death or disease recurrence for potential intensification of treatment to improve these outcomes. Thus, with the search for CTCs and biomarkers before and after treatment, it is possible to personalize the treatment employed to maximize the chances of cure and minimize the sequelae of the treatment, improving survival with quality of life. Below is a technical summary of the work and its results:Prognostic impact of circulating tumor cells and potential predictive role of treatment response in locally advanced epidermoid carcinoma of the head and neck. São Paulo; 2019. [Doctoral Thesis - Antônio Prudente Foundation].Introduction:The prognostic role of circulating tumor cells (CTCs) in locally advanced head and neck cancer (CCPLA) has not yet been determined, due to conflicting results in previous studies, most using cytokeratin-dependent techniques for the identification and counting of CTCs. The primary objective of this study is to determine the detection rate using the ISET method, the prognostic role and potential predictive role of CTCs in CCPLA.Methods:Prospectively, blood samples from patients with non-metastatic CCPLA, stages III/IV, were analyzed for CTCs before and after treatment, in two scenarios: initial curative surgery and adjuvant radiation therapy (RT) and candidates for non-surgical strategies (unresectable or organ preservation) with RT concomitant with chemotherapy (QT) or cetuximab, whether or not preceded by induction QT (QTI).Results:83 patients and the detection rate of CTCs were included. Baseline It was 94 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} (78/83). The CTC count was significantly correlated with survival, with a relative increase of 18 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} (HR=1.18; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.06-1.31; p<0.001), 16 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} at risk of progression (HR=1.16; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.04-1.28; p=0.004) and a reduction of 26 {46cf1a6c7461493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} na chance of a complete response to treatment (OR=0.74; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.58-0.95; p=0.022) for each increase in a CTC. Patients with CTCs < 6.5/mL had a two-year overall survival (OS) estimate of 85.6 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} x 22.9 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e12b94daa5b61391} for CTCs ≥ 6.5/mL (HR=0.18; 95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.06-0.49; P<0.0001) and patients with CTCs ≤ 3.8/mL an estimate of progression-free survival (PFS) at two years of 71.8 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} x 37 {46cf1a6c7461ff493d31bdca70d45967bd1 ce7048f85e123712b94daa5b61391} for CTCs > 3.8/mL (HR=0.32; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} :0.15-0.67; p=0.001). After treatment, high CTC counts (cutoff 6.6/mL) were significantly correlated with worse SG (HR=0.12; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.06-0.40; p<0.001) and SLP (HR=0.19; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f31bdca70967bd1ce7085f123712b94daa5b61391}: 0.06-0.59; p=0.001). In the non-surgical treatment subgroup (n=67), the presence of microemboli (ME) was significantly correlated with worse OS (HR=3.01; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.06-8.52; p=0.020) and SLP (HR=3.84; CI95 {46cf1a6c7461ffce493d31bdca70d9671bdca70d9671bdca70d9671bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d967bdca70d9671bdca707048f85e123712b94daa5b61391}: 1.62-9.11; p<0.001). In this subgroup, high CTCs (>3.8/mL) and ME were identified as potential predictors of the QTI benefit. MRP-7 expression in ME Baseline was related to the worst SG (HR=3.49; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.01-12.04; p=0.047) and SLP (HR=3.62; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 1.08-12.13; p=0.037) and expression of TFGβRI in CTCs after treatment for the worst OS (HR=3.60; 1.03-12.59; p=0.032). Expression of beta-tubulin III in CTCs was associated with worse OS in patients receiving QTI (p=0.012). Patients with favorable CTC kinetics had better OS (HR=0.22; IC95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.07-0.67; p=0.004) and SLP (HR=0.33; CI95 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391}: 0.13-0.84; p=0.015).Conclusions:Count of CTCs Baseline were correlated with survival and response to treatment and, together with ME, are potential predictors of the benefit of QTI. High CTC counts after treatment and unfavorable kinetics were also prognostic. Biomarker expression in CTCs and ME plays a prognostic and predictive role in CCPLA.
Make a donation to the Cura Project and guarantee your ticket to the concert of the Spanish singer Alba and conductor Osmar Barutti.
On 14/06, at Blue Note São Paulo, the Spanish singer Alba and the conductor Osmar Barutti, known for being the arranger of the show Jô Soares, come together for a very special evening where they present reinterpretations of the great jazz standards by composers such as Duke Ellington, Ira & George Gershwin, etc...
During the Show, the 1st Renata Thormann Procianoy Prize will be awarded as an incentive and recognition to the young researcher doctor and to encourage philanthropy.
SEP 2. — BENEFIT SHOW
LOCAL — BLUE NOTE São Paulo - Av. Paulista, 2073 - National Complex - Consolação, São Paulo - SP
DATE — 14/06
SCHEDULE — The Blue Note balcony with a view of Av. Paulista will be available to event guests starting at 8 p.m. Expected start of the show at 22:30.
MINIMUM AMOUNT FOR DONATION — R$ 200.00 (each R$ 200.00 in donation will entitle you to a ticket)
BOX OFFICE CONTACT — (11) 94545-1511 (WhatsApp)
Donations can be made safely through the platforms PayPal (for a minimum donation or a larger amount) or PagSeguro (for minimum donation)
If you prefer, it is still possible to make your donation by bank transfer to the account below. After the deposit, please send the receipt, your name and CPF/CNPJ number to contato@cura.supersoma.me.
Cura Project Institute Association
CNPJ: 033,188,607/0001-04
Banco Santander (Bank Code: 033)
Agency: 0995
Current Account: 13,001,079-8
Upon confirmation of payment, our team will contact you to indicate the procedure for collecting the tickets.
On June 14, in São Paulo-SP, the Spanish singer Alba and the conductor Osmar Barutti, known for being the arranger of the show Jô Soares, come together for a very special evening where they present reinterpretations of the great jazz standards by composers such as Duke Ellington, Ira & George Gershwin, etc... The show aims to raise funds for cancer research.
SEP 2. - LOCAL BENEFIT SHOW - BLUE NOTE São Paulo - Av. Paulista, 2073 - Consolação, São Paulo - SPDATE - 14/06SCHEDULE — 22:30 - The Blue Note balcony overlooking Av. Paulista will be open starting at 8 p.m.DONATION AMOUNT - $200.00 (Donors will win 1 ticket for the SET 2 show.) Soon we will announce how you can purchase your vacancy. This initiative is supported by:
Check out the interview with Dr. Otto Mezinger, an oncologist at the Dana Faber Cancer Institute and the Havard Medicine School.
Art Basel Miami, one of the leading global art fairs, had the Cura Project Institute as a social responsibility entity supported by Brazilian curator Adriana Rede's 2018 program.
The theme of the fair this year was Modern and Contemporary art. Among the participants in the fair was visual artist and photographer Vik Muniz, one of the most important Brazilian artists on the world stage. He is currently known for using unusual materials in his works, such as garbage, sugar and chocolate.
The president of Cura, Fernanda Schwyter, participated in the course “The Artistic Vanguards”, the lecture “Women in Art”, as part of the Miami Art Week activities, and also of the visit monitored by the curator, at the Miami Art Basel Fair. We did a short interview with Curator Adriana Rede:1- What is the importance of Art Basel Miami?Miami Art Basel, the largest art fair in the United States, brings together 268 galleries from 34 countries. It is considered the most important fair in the world for the Latin American art market. In 2018, 14 Brazilian galleries participated, with renowned national and international artists. Its importance in the art system is due to the dissemination of thought and educational process through issues addressed in art, both in the past and in our time.2- Why did you support CURA? Or what is the importance of this partnership?Today, political/social issues are part of the contemporary art repertoire and many artists and museum institutions have been involved with specific projects. For me, supporting CURA and its dissemination are a form of engagement, being at the forefront of future trends with the tools I have as a curator.
Fernanda Schwyter, president of the Cura Project Institute, and the curator Adriana Rede. Adriana Rede, has a degree in Social Communication, Curatorship, Expography and Art Criticism. She co-curated at MAM SP and curated exhibitions at museums such as MAJ Joinville, SESC Curitiba, Caixa Cultural SP and MAC USP. For 12 years, she has been curator of the charity exhibition Chapel Art Show, which has existed for 50 years and with more than 100 participating artists. Curator responsible for the Chapel Art Collection collection and editorial coordination of the publications in the collection. She curated individual shows by several artists: Florian Raiss (2009), Baravelli (2010), Antonio Henrique Amaral (2011), Claudio Tozzi (2012), Judith Lauand (2014), Nelson Leirner (2015), Katia Canton (2015), Hugo França (2017), German Lorca (2017), Ricardo de Vicq (2018/Germany) Curator of the official exhibition of the Curitiba Biennial circuit - 25 years. Member of the APCA-São Paulo Art Critics Association. Speaker in Brazil and abroad.
The Cura Project was selected to be one of the programs supported by the Brazil Foundation. The campaign began on September 27 and will end on November 27. Help transform science into treatment. Research Saves Lives! Embrace CURA yourself too! Make your donation at the link: https://abraceobrasil.org/pt-br/projetos/projetocura/
Cura, in partnership with Grupo Barbosa Lima, is promoting the holding of 12 musical performances, with artists from different genres of Brazilian music, such as: samba, rock, instrumental, MPB, among others. The income from the Shows will be used to finance research in the area of oncology. The project is collected through the Tax Incentive Law, such as ICMS, ISS and IPTU, both from legal entities and individuals.Against games:
Dr. Carlos Barrios, comments directly from Munich, Germany during the European Oncology Congress - ESMO, on the importance of clinical research in the evolution of cancer treatments.
Dr. Marcio Debiasi, comments directly from Munich, Germany during the European Oncology Congress - ESMO, on the importance of the CURA project for the development of clinical research in Brazil.
Dr. Gustavo Werutsky, comments directly from Munich, Germany during the European Oncology Congress - ESMO, some examples of clinical research promoted by LACOG.
Today I would like to share with you another practical example showing the importance of carrying out researches, here in Brazil (and in South America?) , at all levels and areas, since the main benefitted is the civil society itself, in other words, each one of us.Dr. Luciano Lauria Dib, a bucomaxillofacial surgeon, faculty member and researcher associated with international universities, in collaboration with Dr. Rodrigo Salazar, a Peruvian researcher, and the University of Illinois, USA, and additional physicians, invented an innovative and much cheaper method to manufacture facial prostheses. This new technique allows them to produce facial prostheses using a regular smartphone, free applications and a common 3-D printer.In addition to saving time and money, such technique enables the restoration of faces and also of the self-esteem among patients who suffered injuries associated with cancer of the mouth, nose, jaw or another area of head or neck.As one can see in previous posts published here on the CURE website, the incidence of cancer of head and neck (many of them associated with the HPV virus) has been increasing in a significant manner. According to statistics published by the Brazilian Ministry of Health, this type of cancer may reach up to 30,000 cases per year (in a near future?) ; as a consequence of such disease, surgical removal of portions of face is required, followed by some type of facial reconstruction. However, many of such patients cannot afford those restorative surgeries.Concerned with such scenario Dr. Dib, in conjunction with a multidisciplinary team — all volunteers, created the Instituto Mais Identidade, a non-for-profit organization, to restore the self-esteem of those patients who had their facial appearance modified. This Institute sponsors the installation of such innovative prostheses in such patients and plans to train additional physicians to use that technique.However, like the CURE Project, the Instituto Mais Identidade still suffers with the lack of resources to disseminate such benefits to thousands of patients.
We need a society more aware of the importance of supporting social responsibility projects and creating a culture of donation, both physical and legal, in order to allow these projects to advance, ranging from the scientific researches to the end product, be it a new medicine, a new treatment or a new technique.By Fernanda Schwyter Coordinator, CURE Project
The CURA Project also took the field on June 15 and called on the main superstars who are active in the attack against cancer. The dinner took place at the house of Dr Fernando Maluf, one of the CURA Ambassadors, was organized by the Director of CURA, Fernanda Schwyter and was attended by several specialists, members of the LACOG - Latin American Cooperative Oncology Group and big names in society, from different sectors, who were honoring this project and contributing to this cause, such as the singer Margarete Menezes, who was the godmother of the first dinner in favor of cancer research.
The ceremony for awarding the certificates of the new CURA Ambassadors took place during the Best Of Asco Congress, on June 15 and 16 in the city of São Paulo. From left to right, Dr. Gustavo Werustky - Director of LACOG; Ambassador Dr. Luis Fernando Correia - doctor and journalist for CBN and Globo News; Ambassador Dr. Jorge Landemann - businessman; Dr. MaX Mano - LACOG Oncologist, Fernanda Schwyter - Director of the CURA Project; Dr. Carlos Barrios - President of LACOG.
Faça como a boutique da designer de moda Adriana Degreas e a clínica do Dr. Jose Couto: mostre para todos seu apoio ao Projeto Cura! Adquira os adesivos do Cura e apoie a luta contra o câncer. Escreva para fernanda.schwyter@lacog.org.br
The Best of ASCO will take place on June 15 and 16 in the city of São Paulo. It is an official ASCO event in partnership with LACOG that aims to present the main studies from the American Congress in Brazil to oncologists who were unable to attend the event. Thus, ASCO provides the complete results and the slides of each study presented and invited professionals (both Brazilian and international) present the results, followed by a discussion of the studies. The Best of ASCO aims to disseminate the latest Oncology research to all Brazilian professionals. In this way, the population benefits indirectly, since more up-to-date and qualified oncologists can provide better treatments and thus improve cancer outcomes in Brazil.
Registrations for professionals in the field are FREE! The schedule can be found at this link.
From June 01 to June 5, 2018, the ASCO - American Society of Clinical Oncology will take place. This annual meeting (ASCO Annual Meeting) is always held in the month of June in Chicago, United States. It is considered the world's largest congress on Clinical Oncology, bringing together more than 30,000 doctors and health professionals from around the world. This event presents the results of the most important cancer studies, many of which have an impact on clinical practice.
Event website: https://am.asco.org/How will LACOG participate in ASCO 2018?Lacog will present 3 abstracts at this important event. Two abstracts refer to the EVITA study — an epidemiological study on cervical cancer in Brazil. This study is in progress (these publications were initial results of the research). This study was developed by LACOG in partnership with EVA (Brazilian Gynecological Tumor Group). The third abstract is a study developed by the GBOT (Brazilian Thoracic Oncology Group) in which LACOG supported the planning, analysis and writing of the results.What type of research was carried out?EVITA is an observational study that collected data from patients treated at their respective institutions. The study continues with the follow-up of patients to assess treatment, quality of life, and survival over time. The GBOT study, on the other hand, collected the results of pathology laboratory tests to assess the prevalence of pd-l1 marker positivity in lung tumors. This study is complete and we will be working on its publication.Were these studies conducted by LACOG member doctors?In the EVITA study, several LACOG researchers were included in their respective hospitals and clinics, comprising all Brazilian regions. All participating doctors are members of LACOG. The supervision, conduct of the study, data analysis and publication were carried out at the LACOG Office in Porto Alegre. The PD-L1 lung cancer study was conducted by a group of investment oncologists from GBOT/LACOG and pathologists from reference laboratories in Brazil. The database and statistical analysis were carried out at the LACOG office, which has personnel specialized in clinical research.What is the importance of these studies?The Cervical Cancer Study (EVITA) is the largest study ever conducted in Brazil on the disease. Its objectives are to characterize the patient population (age, age group, income, personal and family history, treatments performed), evaluate screening through the Pap smear (how many women did it, why didn't) and study the quality of life of these patients before and after treatment, using evaluation criteria from the EORTC (European Organization for Research and Treatment of Cancer). The 3 abstracts are available on the LACOG website, the last 3, dated as 2018. The following link is: http://lacog.org.br/publications
A study presented by the Ministry of Health shows that more than half of the young population in Brazil is infected with HPV.
These are data that attract attention: HPV is a virus that can cause various types of cancer, such as that of the cervix, penis, anus, and more recently it has been associated with throat cancer (tonsils and base of the tongue).
Throat cancer is most often associated with smoking and alcoholism. But that has changed in several countries around the world, with HPV being the main causative factor. In some countries in Europe and the USA, throat cancer caused by HPV is already considered an epidemic by some scholars. In Brazil, data show that most of these tumors are still related to tobacco and alcohol.
But that is changing. We currently have several patients with throat cancer caused by HPV even in Brazil.
What about the vaccine? Help? Will it lower the risk of this cancer?
Yes! The HPV vaccine prevents a person from becoming infected with the cancer-causing HPV viruses. If there's no infection — there's no cancer caused by the virus.
And is it effective at preventing infection?
Yes! At the American Oncology Congress this year, a study was presented that evaluated oral infection with the HPV virus after vaccination of young adults. The vaccine showed an efficacy of 88% {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} in reducing the rate of oral cavity infection in vaccinated individuals.
Brazil has already incorporated the HPV vaccine into the national vaccination schedule. For girls in 2014 and for boys in 2017. However, the adherence rate to the vaccine is still insufficient.
Each of us has to do our part. The question IS CANCER CURABLE? — it should not be answered by doctors alone.
Each one of us has a responsibility to seek a cure for cancer: whether by taking proper care of the patient, researching, adopting healthy lifestyle habits and, FINALLY, VACCINATING AGAINST HPV.
Text prepared by Dr. Aline Chaves — member of LACOG
On the occasion of World Cancer Day (February 4), EORTC - European Organization for Research and Treatment of Cancer and BIG - Breast International Group, entities that support LACOG - CURA, prepared a press release with the objective of increasing awareness of male breast cancer.
Breast cancer is about 100 times less common in men than in women. Due to the rarity of this disease, it is normally excluded from clinical trials and doctors generally use the treatment applied to women. In new investigations carried out, the scientists demonstrated the feasibility of carrying out a therapeutic clinical trial in a rare patient population, which represents 1 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} of all breast cancers. The American Cancer Society estimates that around 2,550 new cases of invasive male breast cancer will be diagnosed in the United States in 2018 and that around 480 men will die from this disease. For more information, click on this link: https://www.cancer.org/conte... /DAM/CRC/PDF/Public/8584.00.pdf
Now, CURA and the ARD Foundation joined forces to raise funds to fight cancer. Look forward to our calendar of events!
Because of World Cancer Day (February 4), the EORTC - European Organization for Research and Treatment of Cancer) and the BIG - Breast International Group, entities that support LACOG - CURA, prepared a press release with the objective of raising awareness about male breast cancer.
Recent findings from international breast cancer research confirm that the disease in men and women is undeniably different and that 1 in 3 men affected by the disease is not treated properly. Breast cancer is about 100 times less common among men than among women. Due to the rarity of the disease, they are generally excluded from clinical trials, and doctors generally use the treatment applied to women. In new research, scientists demonstrated the feasibility of pursuing a therapeutic clinical trial in a rare patient population, which represents 1 {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} of all breast cancers. American Cancer Society It is estimated that in the USA about 2,550 new cases of invasive male breast cancer will be diagnosed in 2018 and about 480 men will die from the disease. For more information, visit this link: https://www.cancer.org/conte…/dam/CRC/PDF/Public/8584.00.pdf
In these difficult days for the country and for public health, EXCELLENT NEWS: the incorporation, by the SUS, of PERTUZUMAB for the treatment of patients with HER2-positive metastatic breast cancer. This represents More LIVES with more QUALITY!!!
See the ordinance that makes the matter official:
Dr. Aline Chaves, an oncologist at LACOG, from the Head and Neck area. A study presented by the Ministry of Health shows that more than half of the young population in Brazil is infected with HPV. These are data that attract attention: HPV is a virus that can cause various types of cancer such as cervical cancer, penis, anus and more recently it has been associated with throat cancer (tonsils and base of the tongue). Throat cancer is most often associated with smoking and alcoholism. But that has changed in several countries around the world, with HPV being the main causative factor. In some countries in Europe and the USA, throat cancer caused by HPV is already considered an epidemic by some scholars. In Brazil, data show that most of these tumors are still related to tobacco and alcohol. But that is changing. We currently have several patients with throat cancer caused by HPV even in Brazil.What about the vaccine? Help? Will it lower the risk of this cancer?Yes! The HPV vaccine prevents a person from becoming infected with the cancer-causing HPV viruses. If there's no infection — there's no cancer caused by the virus.And is it effective at preventing infection?Yes! At the American Oncology Congress this year, a study was presented that evaluated oral infection with the HPV virus after vaccination of young adults. The vaccine showed an efficacy of 88% {46cf1a6c7461ff493d31bdca70d45967bd1ce7048f85e123712b94daa5b61391} in reducing the rate of oral cavity infection in vaccinated individuals. Brazil has already incorporated the HPV vaccine into the national vaccination schedule. For girls in 2014 and for boys in 2017. However, the rate of adherence to the vaccine is still insufficient. Each one of us has to do our part. The question IS CANCER CURABLE? — it should not be answered by doctors alone.Each one of us has a responsibility to seek a cure for cancer: whether by taking proper care of the patient, researching, adopting healthy lifestyle habits and, FINALLY, VACCINATING AGAINST HPV.
Follow CURA on social media
© 2023 Cura Project Institute. All rights reserved.
.jpg)
_20250718_163507_0000.png)
